Opexa is focused on becoming a leader in Precision Immunotherapy™ and believes its T-cell platform has potential across a broad range of autoimmune disorders. Opexa’s lead drug candidate, Tcelna, is in a Phase IIb clinical trial ( the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis patients. Tcelna has received U.S. FDA Fast Track Designation in SPMS.

With Opexa having entered into an option and license agreement with Merck Serono, Tcelna could become the product of choice for patients with SPMS. Presently, there are very limited treatment options for SPMS patients and a successful development could translate into blockbuster potential for Tcelna.

The replacement value of the company is multiples of the present market cap, thereby providing what we believe to be an attractive risk/reward profile for long-term investors.

Opexa has constituted an esteemed scientific advisory board and a goal-oriented management team focused on value creation for patients, employees and shareholders.